spacer
home > epc > Summer 2013
PUBLICATIONS

European Pharmaceutical Contractor

epc
Summer 2013

   
Text
PDF
bullet
introduction

Editor’s Letter

Editor's letter

Graham Hughes gives readers a brief outline of his pick of this issue’s articles.

 
view
download pdf
bullet
Marketplace & Business: Translation Feature
Big Pharma 2.0

What Does the Future Hold?

Hellmuth Broda at Infosys explores some of the achievements that the pharmaceutical industry has gained over the past few decades, as well as giving some predictions for what we could expect to see as the 21st century unfolds.
 
view
download pdf
bullet
Clinical Trials
Quality Analysis

What Price Quality?

Robert J Hayes at Cold Chain Consultants (UK) Ltd outlines some of the key factors that must be considered in order to understand why failure occurs in clinical trials, including the ability to understand the Cost of Quality, as well as how to avoid poor quality.
 
view
download pdf

Clinical Trials

Virtual Trial Methods

The increase in drug development costs, in addition to the over-saturation of the market, has meant that companies must expand their outreach, while contracting their costs. Kai Langel at eClinicalHealth Ltd believes that this may be possible through virtual trials.

 
view
download pdf
bullet
Legal & Regulatory
Non-Animal Toxicology Testing

Alternative Action

Animal testing methods in drug development and testing are increasingly becoming less and less accepted in today’s society. Jarrod Bailey at the New England Anti-Vivisection Society discusses some of the possible alternatives.
 
view
download pdf
bullet
Clinical Research

In Conclusion

Ignorance is Far From Bliss

Vaccinations are essential for society, otherwise we risk epidemics of once-common diseases that have been virtually eliminated, argues Graham Hughes.

 
view
download pdf
bullet
Science & Innovation
Animal Testing Alternatives

A Driving Force

Using examples from the pharmaceutical and cosmetics industries, Andre Menache at Antidote Europe develops the argument for non-animal toxicology testing, providing evidence as to why other options are increasingly being considered.

 
view
download pdf
Toxicology

New Rules for New Tests

The world of toxicology is facing enormous changes. Daryl S Paulson at BioScience Laboratories, Inc delves into the world of animal testing, and presents some non-animal methods.
 
view
download pdf
bullet
DATA MANAGEMENT
Data Analytics

A Change in Time

Scott Setrakian at Applied Predictive Technologies explores the changes in which data is stored, analysed and managed, including ensuring that the results are more precise and less open to common errors.
 
view
download pdf
bullet
Risk Management
Facility Protection

Risky Business

Mark Lamond at FM Global realises that the process of managing risk is more of an issue today than it has ever been, and to combat this growing demand, companies must address some of the challenges associated with effective risk-management.
 
view
download pdf
Risk-Based Monitoring

An Important Decision

Recent guidance has outlined the need for quality risk management to aid pharma companies in their quest for discovery. However, as Marta Gibala and Michael Sigmund of SSS International Clinical Research point out, many are reluctant to commit to it.
 
view
download pdf
bullet
Review
Event Review

Euro Exchange

Graham Hughes reviews the DIA Euromeeting, which took place in Amsterdam in March this year.
 
view
download pdf
bullet
Regional Focus
Regional Focus

Good Strategy

In the second of a two-part article, industry reporter Nick Charles returns to the East to continue his analysis of China’s life sciences industry. In this final installment, he focuses on the importance of timing, investment and partnerships.
 
view
download pdf
Clinical Trials: Serbia

A Region Reborn

Jelena Barjaktarovic, Maxim Belotserkovsky, Mirjana Jovanovic and Melita Zonic at PSI CRO AG explain why the future of clinical trials may shift to a Balkan state, as well as weighing up some potential problems that must be overcome.

 
view
download pdf

Research and Development
Stimulating Innovation in R&D

Better Together

It is necessary for pharma companies to constantly evolve in order for them to remain relevant and in demand. Gilles Toulemonde at Inova Software outlines some possible ways in which this innovation can be maintained.
 
view
download pdf
Metabolomics

Mapping the Maze

As metabolomics emerges as a leading technology, Nicolas Schauer and Dierk-Christoph Pöther at Metabolomic Discoveries explain some of the key benefits that this novel tool may present to biochemical mechanisms, diseases and nutrition.
 
view
download pdf

Interview
Interview: David Underwood

Hitting New Targets

Founding CEO and Chairman of Quanticate speaks to EPC about some of the daily challenges that he faces, as well as the possible future direction of the industry.
 
view
download pdf

Interview: Heather Fraser

Life Lessons

EPC talks to IBM about the clinical trials sector, particularly on what companies must do in order to keep running smoothly.

 
view
download pdf
   
spacer



Published quarterly in
February, May,
August and November

News and Press Releases

Domestic companies predict a 16% growth in the South Korean pharma market during CPhI Korea

CPhI Korea, organized by UBM, closed its doors in Seoul after another record-breaking event that attracted 4,300 attendees and 147 exhibitors. During the event, UBM undertook an in-depth onsite survey of both international and domestic attendees, with domestic companies reporting a headline growth in the order of 16% across the South Korean pharma economy.
More info >>

White Papers

Time lapse photography to demonstrate the potential antimicrobial abilities of Dycem contamination control flooring

Dycem

A defined volume of bioluminescent reporter bacteria was deposited onto 20 mm x 20 mm coupons of Dycem flooring, vinyl tile and ITW Alma tacky mat. Through monitoring of bacterial bioluminescence, metabolic inhibition was observed on all three surfaces however the effect occurred more rapidly on Dycem flooring than on vinyl or ITW Alma. Recovery counts after three hours of exposure to the floor surfaces showed between a 65% and 100% decrease in the number of viable organisms recovered from Dycem flooring compared to controls. On vinyl and ITW Alma flooring, there were slight increases in the number of viable survivors recovered compared to controls. Dycem flooring inhibited the metabolic activity and reduced the number of viable survivors recovered of Salmonella enterica Serovar Typhimurium DT104 pGLITE. It remains unclear as to whether this effect is attributable to the impregnated biocide or rapid drying of the inoculum on this surface.
More info >>

Industry Events

Pharmapack Europe 2018

7-8 February 2018, Hall 7.1, Paris Expo, Porte de Versailles, Paris.

As Europe's dedicated Pharmaceutical Packaging and Drug Delivery event, Pharmapack is the industry's go-to place to kick-off the year.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement